Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

Abasaglar® (insulin glargine) : Transitioning from insulin detemir

Based on analyses of trials, a dosage reduction may be warranted when transitioning from insulin detemir to Abasaglar .

Detailed Information

No dedicated trial has been conducted to investigate patients transitioning from IDet to Abasaglar.

To compare insulin doses in patients treated with IGlar or IDet, Wallace et al conducted an analysis that included

  • 5 large RCTs in patients with T2DM, and

  • 2 large RCTs in patients with T1DM.1

To achieve the same glycemic control, patients treated with IDet required an average 38% higher dose of insulin compared with patients treated with IGlar (Table 1 ).1

Dailey et al conducted a pooled analysis of 22 RCTs in patients with T2DM to compare insulin doses in patients treated with IGlar or IDet. To achieve a similar reduction in HbA1c levels, patients treated with IDet required a 31% higher mean insulin dose compared with patients treated with IGlar ( Table 1).2

Table 1. Analysis of Doses in Patients Treated With Insulin Glargine or Insulin Detemir in Randomized Controlled Trials1,2



Patient Population

Doses of Insulin Glargine Compared With Insulin Detemir for Similar HbA1c Reduction

Wallace et al

7 RCTsa

T1DM and T2DM

8.0%-77.2% (average 38%) higher detemir dose

Dailey et al

22 RCTs


0.59 (0.07)b units/kg for insulin detemirc

0.45 (0.02)b units/kg for insulin glargine

Abbreviations: HbA1c = glycated hemoglobin; RCT = randomized controlled trial; T1DM = patients with type 1 diabetes mellitus; T2DM = patients with type 2 diabetes mellitus.

a Five RCTs in patients with T2DM and 2 RCTs in patients with T1DM.

b Mean (SE).

c Represents a 31% higher insulin dose compared to insulin glargine.

Wallace et al concluded that since higher doses of IDet may be needed to obtain similar glycemic control, prescribers may want to consider a dosage reduction when transitioning from IDet to IGlar in order to reduce the risk of hypoglycemia that may result when using a unit-to-unit conversion.1

General Dosing Guidelines When Transitioning to Abasaglar

If transitioning from a treatment regimen with an intermediate- or long-acting insulin, other than an IG-100 product, to a regimen with Abasaglar,

  • a change in the dose of the basal insulin may be required, and

  • the doses and timing of concurrent rapid- or short-acting insulins or other concomitant antihyperglycemic medications may need to be adjusted.3


1. Wallace JP, Wallace JL, McFarland MS. Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose? Ann Pharmacother. 2014;48(3):361‑368. http://dx.doi.org/10.1177/1060028013518420

2. Dailey G, Admane K, Mercier F, Owens D. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther. 2010;12(12):1019-1027. http://dx.doi.org/10.1089/dia.2010.0063

3. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.


Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

HbA1c = glycated hemoglobin

IDet = insulin detemir

IG-100 = insulin glargine 100 units/mL

RCT = randomized controlled trial

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

Date of Last Review: January 07, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request